Indapamide in a single daily dose in the treatment of hypertension. A multicentre trial in private practice.
In a multicentre trial a single daily oral dose of indapamide 2.5 mg (Natrilix; Servier) was prescribed to 387 hypertensive patients by their general practitioners for a period of 12 weeks, the common protocol permitting adjuvant therapy where necessary. Excellent control was achieved in indapamide alone and in 51.2% of 123 patients with more severe hypertension who were treated with indapamide combined with other hypotensive agents. Non-limiting side-effects occurred in 0.03% of patients receiving indapamide alone. The drug is considered a safe and effective agent for the treatment of mild-to-moderate hypertension (diastolic blood pressure between 90 and 129 mmHg in private practice.
D000328:Adult; D000368:Aged; D001794:Blood Pressure / Q000187:drug effects; D002986:Clinical Trials as Topic; D004232:Diuretics / Q000008:administration & dosage*; D005260:Female; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*; D007190:Indapamide / Q000008:administration & dosage*; D008297:Male; D008875:Middle Aged
D004232:Diuretics; D007190:Indapamide